X-Therma is selected by the California Institute of Regenerative Medicine (CIRM) for highly competitive funding to fuel X-Therma’s development to advance critical stem cell manufacturing processes.


X-Therma is competitively selected for a third US Department of the Army SBIR Phase II SBIR contract. X-Therma’s CryomatrixTM is a new pipeline of non-toxic and hyper-effective cryoprotectants in development for cell, tissue, and organ banking.


X-Therma CEO Dr. Xiaoxi Wei’s career development story is featured in Chemical &Engineering News (C&EN, Volume 95 Issue 23 | p. 23| Issue Date: June 5, 2017). An enlightening story of her inspiration to start the startup journey guided by a childhood dream.